****** | Patrys CEO and MD, Dr James Campbell - YouTubeIt was encouraging tosee the market respond positively to Patrys’ (ASX
AB) announcement last week regarding our preclinical study highlighting the potential for using our deoxymab antibodies as targeting agents in antibody drug conjugates (ADCs).
I had the pleasure of being interviewed by Kara Ordway on ****** to discuss this study, and other recent milestones, which I’m pleased to share today.
My bold above............not so sure where he got the positively bit from............looked like the market reacted adversely IMO
Ann: PAT-DX3 proof of concept as potential ADC targeting antibody, page-59
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $10.97K | 3.626M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 31554019 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27089307 | 15 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |